The HERA trial established the role of trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer patients by demonstrating significantly improved disease-free survival (DFS) and overall survival (OS) [40, 41]. This evidence concerns the gene ERBB2 and breast cancer.